Lung Cancer Clinical Trial: Lenvatinib (E7080) for KIF5B-RET-Positive NSCLC
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
- November 27, 2015
- 1 min read
A Phase 2 clinical trial evaluating lenvatinib (E7080), a targeted therapy agent, in KIF5B-RET-positive lung cancer patients is being conducted across Taiwan, Japan, the United States, Hong Kong, and Thailand.
Trial Period: April 2013 – April 2016 Target Enrollment: At least 20 subjects with KIF5B-RET translocation
Eligibility Criteria:
- Age 18 or older
- Diagnosed with lung cancer
- KIF5B or RET translocation confirmed
- Able to receive treatment
- Measurable tumor by RECIST 1.1 criteria
- Blood pressure controlled
- Performance status (PS) 0 or 1
Exclusion Criteria:
- Received other anti-tumor agents within 21 days prior to first lenvatinib dose
- Severe unrecovered adverse events from prior anti-tumor therapy
- Serious cardiac disease
- Gastrointestinal dysfunction
- Surgery within 3 weeks prior to first lenvatinib dose
Trial Description (English):
This is a Phase 2, open-label, safety and activity study of lenvatinib in subjects with KIF5B-RET-positive adenocarcinoma of the lung and other confirmed RET translocations. At least 20 subjects with KIF5B-RET will be treated and will receive lenvatinib at a starting dose of 24 mg orally, once per day. Additional subjects with other RET translocations will be treated with lenvatinib at a starting dose of 24 mg orally, once per day. (ClinicalTrials.gov)
Source: http://www.eisai.co.jp/news/news201435pdf.pdf
Lung Cancer | RET-Positive | Targeted Therapy | Lenvatinib
-
Clinical Trial Medications
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1
Figure 2
Figure 3
Figure 4